Phase 4 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with retinal vein occlusion (a blockage in the blood vessels of the retina) that meets recognised international diagnostic standards
• People aged between 18 and 80 years old (any gender)
• People who have not previously received any treatment for their retinal vein occlusion-related fluid build-up in the eye — including no anti-VEGF injections, steroid treatments, or laser therapy
• People whose OCT scan (a special eye imaging test) shows a central retinal thickness of 300 micrometres or more, indicating swelling in the eye
• People whose vision in the affected eye falls within a specific range — roughly between 20/400 (severely reduced vision) and 20/40 (mildly reduced vision) based on a standardised eye test
• People who are willing and able to sign a consent form and attend all required follow-up appointments

Who may not be able to join:

• People who have other eye conditions that can cause fluid build-up in the retina, such as diabetic retinopathy or eye inflammation (uveitis)
• People whose eye imaging is affected by cloudiness inside the eye, such as a severe cataract or bleeding in the vitreous (the gel inside the eye)
• People who have already received anti-VEGF injections, steroid treatments, or laser therapy to the retina
• People who have taken steroid tablets or immunosuppressant medications (drugs that lower the immune system) in the three months before joining
• People with poorly controlled health conditions such as high blood pressure, diabetes, or liver or kidney problems, as well as people who are pregnant or breastfeeding
• People who are known to be allergic to mecobalamin or conbercept (the medications being studied in this trial)
• People who are unable to cooperate with the required eye examinations or follow-up visits, or who have participated in another clinical trial within the past year

Important: Always verify eligibility with the trial site directly before applying.